Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Colon | Rectum
What is the purpose of this trial?
This is a phase II, open-label, non-randomized study in subjects with histologically confirmed diagnosis of left-sided RAS WT advanced adenocarcinoma of the colon or rectum who have not received prior systemic therapy for metastatic disease.
- Trial withAcademic GI Cancer Consortium (AGICC)
- Start Date01/12/2022
- End Date09/01/2022
- Last Updated01/13/2022
- Study HIC#2000026787